Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of cancer
3.2.1.2 Advancements in research and development
3.2.1.3 Personalized medicine and biomarker development
3.2.2 Industry pitfalls & challenges
3.2.2.1 High treatment costs
3.2.2.2 Risk of side effects associated with the treatment
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Monoclonal antibodies
5.3 Cancer vaccines
5.4 Immunomodulators
5.4.1 Checkpoint inhibitors
5.4.2 Immune checkpoint modulators
5.4.3 Other immunomodulators
5.5 Cytokines
5.6 Oncolytic viral therapies
Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Lung cancer
6.3 Breast cancer
6.4 Colorectal cancer
6.5 Melanoma
6.6 Prostate cancer
6.7 Pancreatic cancer
6.8 Other cancer types
Chapter 7 Market Estimates and Forecast, By End-Use, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Specialty clinics
7.4 Cancer research centers
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AbbVie Inc.
9.2 Amgen Inc.
9.3 AstraZeneca PLC
9.4 Bayer AG
9.5 Bristol-Myers Squibb Company
9.6 Celldex Therapeutics, Inc.
9.7 Eli Lilly and Company
9.8 F. Hoffmann-La Roche Ltd.
9.9 Gilead Sciences, Inc.
9.10 GSK plc
9.11 Immunocore Holdings plc
9.12 Johnson & Johnson
9.13 Merck & Co., Inc
9.14 Novartis AG
9.15 Pfizer Inc.
